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a b s t r a c t
Objective: Fetal exposure tomaternal hypercholesterolemia increases the extent of fatty-streak formation
in fetal aortas as well as the rate of progression, and may therefore increase coronary heart disease
(CHD) risk later in life. We hypothesized that the risk of CHD in untreated individuals with familial
hypercholesterolemia (FH) is more extreme when the disease is transmitted maternally.
Methods: In a large Dutch pedigree carrying the V408M mutation in the low-density lipoprotein (LDL)
receptor gene, 161 individuals over seven generations were identiﬁed for which FH status and par-
ent of origin of FH were known. We calculated standardized mortality ratios (SMR) and compared the
consequences of maternal and paternal inheritance of FH by Poisson regression analysis.
Results: Maternally inherited FH was associated with signiﬁcantly higher excess mortality than FH trans-
mitted by fathers (relative risk 2.2; p=0.048): the SMR of maternal inheritance was 2.49 (95% conﬁdence
interval (CI) 1.45–3.99; p=0.001), whereas it was not signiﬁcantly increased in paternally inherited FH
(SMR 1.30, 95% CI 0.65–2.32; p=0.234).
Conclusion: Mortality rates are more increased when FH is inherited through the mother, supporting the
fetal origin of adulthooddiseasehypothesiswith all causedeath, themost indisputable outcomemeasure.
Future research should explore safe options for cholesterol-lowering therapy of pregnantwomenwith FH
ourabin order to prevent unfav
. Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant
isorder characterized by high levels of low-density lipoprotein
holesterol (LDL-C) and as a consequence severe risk of coronary
eart disease (CHD) and premature death when left untreated [1].
he onset of CHD symptoms, however, shows substantial varia-
ion among individuals with FH. Unfortunately, both classical and
ereditary risk factors cannot accurately predict who will ulti-
ately develop CHD.
Increasing evidence suggests that the risk of metabolic and
ardiovascular disease later in life may be inﬂuenced by the envi-
onment in utero, the so-called “fetal origins of adulthood disease
ypothesis” as ﬁrst described by Barker et al. [2,3]. Prenatal effects
n CHD risk later in life have been subject to numerous studies,
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but so far, most research has focussed on the effects of intrauterine
undernutrition, whereas maternal hypercholesterolemia has only
recently begun to raise some scientiﬁc interest. In fact, elevated
LDL-C in themotherhasbeenassociatedwith fatty streak formation
in the fetal aorta and a more rapid progression to atherosclero-
sis later in life [4,5]. We hypothesized that the parent of origin
of FH might therefore in part determine CHD risk: only maternal
inheritance of FH exposes a fetus to the consequences of parental
hypercholesterolemia. Because of possibly teratogenic effects of
statins and gastro-intestinal side-effects of bile-acid sequestrants,
pregnant women are preferably not treated with lipid-lowering
drugs [6,7]. However, the consequences of maternal hypercholes-
terolemia for the newborn are unknown and may have been
underestimated due to the large time lag between exposure and
consequences. To study the consequences of maternally inherited
FH, we compared individuals who inherited FH maternally and
those who inherited through the father in a large FH pedigree, in
Open access under the Elsevier OA license.which the transmission lines of the V408M mutation in the LDL
receptor gene were known for a large number of family members
over seven generations [8]. The V408M mutation results in more
rapid degradation of LDL receptors and unambiguously leads to
























































Fig. 1. Part of the pedigree as an example of assessment of FH status and parent of
origin. Dashed lines indicate a part of the pedigree has been removed for the sake
of clarity. Circles represent females; squares represent males. A and B are the most
early ancestors, of whom is not known who had FH. C, D, E, F, and G can be assigned
to have had FH due to transmission to later generations. H is unknown (50% chance)
because he did not have any offspring. I, J, and L have been genetically tested. K, M,
and N have not (yet) been tested and therefore still have 50% chance. Of all certain
FH carriers, D, E, G, I, and J inherited maternally and L and F paternally. The parentJ. Versmissen et al. / Ather
igh cholesterol levels and increased CHD risk [9–12]. We used all




Data were collected from a large pedigree consisting of 412
escendants in eight generations as described in detail previ-
usly [8]. Three index cases with the V408M mutation (the new
omenclature according to the human genome variation society
ecommendations would be p.V429M) in the LDL receptor gene
ere identiﬁed during routine cholesterol screening (n=2) and
fter a myocardial infarction (n=1) [13]. The untreated probands
ad mean fasting total serum cholesterol concentrations of 10.24,
.20, and 12.78mmol/l, respectively [8]. The molecular diagno-
is of familial hypercholesterolemia was based on the presence of
he V408M mutation, and since they carried the mutation on an
dentical haplotype, they were expected to be (distantly) related.
enealogical research and molecular screening were used to col-
ect all carriers of the V408M mutation in the pedigree. One pair of
ncestors shared by and connecting the three probands was identi-
ed. All livingdescendents of this pairwere screened for theV408M
utation. Only persons for whom diagnosis of FH was certain,
.e. proven carriers of the mutation and individuals on the trans-
ission line of the mutation were included (n=164). For the ﬁrst
eneration, FH status could not be assigned. The second generation
as excluded (n=3), because we had no information about which
arent transmitted the mutation (Fig. 1). The transmission lines
hrough this large pedigree connecting the probands are shown
n the original paper describing this pedigree [8]. The molecular
nd genealogical studies were approved by the hospitals’ review
oards, and all family members studied gave informed consent.
.2. Statistical analysis
The standardized mortality ratio (SMR) was calculated by com-
aring mortality in the pedigree with the mortality in the general
utch population [8]. The SMR is the ratio of observed to expected
umber of deaths. The expected number of deaths is calculated by
ultiplying the total number of years lived by the people in the
edigree in each calendar period in each age and sex category by
he age and sex speciﬁc mortality rates of the Dutch population for
ach calendar period.We ignored the ﬁrst two decades of life for all
eople in thepedigree sincedescendants had to liveuntil reproduc-
ive age before they could pass on the gene mutation and data on
uvenilemortalitymight have been incomplete in the 19th century;
lso, mortality before this age is unlikely to be a consequence of
eterozygous FH.Wecomparedmortality risk betweenpeoplewho
nherited FHpaternally and thosewho inherited itmaternally using
oisson regression (relative risk) adjusted for the differences in dis-
ribution of sex, calendar period and age category. The observation
eriod was censored in 1990 when statins became available.
. Results
A schematic drawing of a part of the pedigree is shown in Fig. 1:
his representsoneof the transmission linesof theV408Mmutation
riginating from one pair of distinct ancestors. Of all 161 persons
ith FH and knowledge of parent of origin of FH, 48 were youngerhan20 at the endof followupon January 31st, 1990, and theywere
xcluded from the analyses. All carriers of the V408M mutation
n our pedigree whose untreated cholesterol levels were available
nvariably had cholesterol levels above the 95th percentile [11].of origin of C’s FH is unknown. L was not included in the analyses because she was
too young at the end of follow-up in 1990.
During 3023 person years, 28 deaths occurred among the 113
patients over 20 years of age. Overall, the SMR was 1.83 (95% conﬁ-
dence interval (95%CI) 1.22–2.64;p=0.002); 1.62 in females (95%CI
0.86–2.77;p=0.062)and2.06 inmales (95%CI1.15–3.39;p=0.008).
A total of 58 patients inherited FH from their mother while 55
patients inherited FH from their father. The SMR of maternally
inherited FH was 2.49 (95% CI 1.45–3.99; p=0.001) while in pater-
nally inherited FH patients the risk was not signiﬁcantly increased
(SMR 1.30, 95% CI 0.65–2.32; p=0.234; Table 1). This difference
in mortality between paternally and maternally inherited FH was
statistically signiﬁcant (Poisson regression: relative risk (RR) 2.2;
p=0.048). The difference between the two types of inheritance
was more pronounced in female offspring: maternally inherited
FH associated with a 2.30 times increased mortality ratio (95% CI
0.99–4.53; p=0.03) while in women who inherited FH paternally
692 J. Versmissen et al. / Atherosclerosis 219 (2011) 690–693
Table 1
SMR according to maternally and paternally inherited FH.
N Person years Observed deaths Expected deaths SMR 95% CI P value
Maternal inheritance
Overall 58 1539 17 6.83 2.49 1.45–3.99 0.001
Males 27 733 9 3.35 2.69 1.23–5.10 0.008
Females 31 805 8 3.48 2.30 0.99–4.53 0.026
Paternal inheritance
Overall 55 1484 11 8.5 1.30 0.65–2.32 0.23
Males 26 714 7 3.8 1.84 0.74–3.79 0.092

















































a, number of persons at risk; SMR, standardized mortality ratio; 95% CI, 95% conﬁde
atients who inherited FH maternally had 2.2 times higher mortality risk relative to
o excess mortality was observed (SMR 0.86, 95% CI 0.23–2.18;
=0.68).Due to small numbers, this differencewasnot signiﬁcantly
ifferent (RR 3.5, 95% CI 0.81–15.2; p=0.09). In males, the SMR
f maternally inherited FH was 2.69 (95% CI 1.23–5.10; p=0.008)
hile in paternally inheritance it was 1.84 (95% CI 0.74–3.79;
=0.092).
. Discussion
We demonstrate that all cause mortality in individuals with
H is more extremely increased when the disorder is inherited
aternally compared with paternal inheritance. This seems more
ronounced in females: mortality in females who inherited FH
aternally was not signiﬁcantly different from that in the general
opulation, but much higher when females inherited the disorder
rom theirmothers. This is to our knowledge the ﬁrst study proving
he “fetal origins of adulthood disease” hypothesis with all cause
eath.
Strong methodological aspects of our study include ﬁrst, that
e used an undisputed outcome measure, all cause mortality, and
econd, that follow-up tookplace before patientswere treatedwith
tatins, and last, that patients were not selected on the presence of
HD; in fact, themajority of individualswere unaware of their con-
ition. This avoids important biases of studies that have addressed
he consequences of maternal hypercholesterolemia during preg-
ancy.Mostprevioushumanstudieswere surrogatemarker studies
n children from families who sought medical attention [14,15]. At
ur own Lipid Clinic, 74% (95% CI 62–83%) of the children below
he age of 18 years have inherited FH paternally. This illustrates
he clear selection bias that occurs on the basis of a higher CHD risk
n males. Such a selection phenomenon might in fact explain why
onstad et al. found that carotid intima media thickness was not
igniﬁcantly different between children who inherited FH mater-
ally or paternally [14]. In our study, this potential selection bias
as avoided by studying multiple generations of one particular
utation, identiﬁed on the basis of only three index cases.
Most studies investigating the consequences of hypercholes-
erolemiaduringpregnancywere invivo and invitro animal studies
16–21]. In a study using mice lacking the ldl receptor (ldlr−/−
ice), ldlr+/− offspring of ldlr−/− mothers had abnormal vascu-
ar responses later in life, as well as increased aortic lesions and
ltered aortic gene expression [16,17]. The ldlr+/− offspring of
dlr+/+ mothers without fetal exposure to hypercholesterolemia
id not show any of these signs of enhanced early atherogenesis.
lso, adult mice lacking one allele of apolipoprotein E (apoE+/−)
escending from hypercholesterolemic apoE−/− mothers had more
evere atherosclerotic lesions than the genetically identical off-
pring of normocholesterolemic wild type (apoE+/+) mothers [18].
his apoE+/− offspring of apoE−/− mothers was also more prone to
he effects of hypercholesterolemia on progression of vascular dis-
ase later in life, a situation very similar to that of an FH child from
n FH mother [19].terval.
e who inherited it paternally (95% CI 1.01–4.08; p=0.048).
Intra-uterine conditions may lead to permanent non-genetic
DNA changes, the so-called epigenetic effects. In mice exposed
to prenatal hypercholesterolemia chromatin modiﬁcations such
as histone methylation, acetylation, and ubiquination were iden-
tiﬁed [19,20]. These changes might alter the regulation of genes
that inﬂuence risk of CHD and mortality later in life. First studies
in offspring of hypercholesterolemic mice indeed showed differ-
ences in gene expression in the offspring up to three months after
birth thatmight havebeen causedby these epigenetic changes [17].
Since LDL-particles at physiological levels only pass the placen-
tal barrier in modest quantities, it is not clear whether chromatin
modiﬁcations result from hypercholesterolemia itself or from the
inﬂammation and oxidative stress caused by the hypercholes-
terolemia in the mother [21]. The presence of these chromatin
modiﬁcations could further conﬁrm our ﬁndings. This has not yet
been studied in offspring of mothers with FH.
During the last trimester of pregnancy in healthy mothers, LDL-
cholesterol is expected to rise by 25–50% [22]. This secondary
hypercholesterolemia is thought to have no effect on the mothers’
lifelongCHD risk [23]. In pregnant FHwomen, the absolute increase
of LDL-C levels is considerably greater than in women without FH,
but the consequences have not been extensively studied [24,25].
Nevertheless, fatty streak formation in the fetal aorta is impres-
sively increased when maternal hypercholesterolemia is present
[4]. In addition, the extent and severity of lesions progress at a
steeper rate in the children who have been exposed to maternal
hypercholesterolemia in utero [5].
Statins are the ﬁrst choice of treatment for FH. These
potent cholesterol-lowering drugs are also reported to be anti-
inﬂammatory and anti-oxidative [26]. However, as reported in
animal studies and birth defect case reports of women that have
coincidentally used statins during pregnancy most statins are
potentially teratogenic, especially the lipophilic compounds that
canpass theplacenta [6,7]. In general, hypercholesterolemiaduring
pregnancy is accepted and statin treatment interrupted [25]. We
recommend thorough examination of teratogenic effects of statins
to exclude the possibility of a recall bias in retrospective studies, as
seen for otherdrugs [27]. Todate, treatmentof FHduringpregnancy
has been reserved for patientswith extreme increases of LDL-C lev-
els and ismainly restricted to bile-acid sequestrants [25]. However,
current policy does not take the effects of maternal hypercholes-
terolemia on the newborn’s CHD risk later in life into account. The
current ﬁnding suggests that an important unmet medical need
exists for cholesterol-lowering medication that is safe for mother
and child.
Our study has a number of limitations. First, we studied a rel-
atively small number of individuals with FH caused by a speciﬁc
mutation. We need replication with other LDL receptor mutations
before our ﬁndings can be generalized. However, we discovered
strong consistencyof resultswith anundisputedoutcome: all cause
mortality. For example, our ﬁnding was consistent in males and
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ay be counterintuitive that the SMR of untreated but paternally
nherited FH was not signiﬁcantly increased, while overall excess
ortality in FH carriers was severe in this pedigree. The point esti-
ate of the SMR of males, who inherited FH paternally, was in
ine with the expected excess mortality but it was not statistically
igniﬁcant (SMR 1.84; p=0.09). The point estimate of the SMR of
emales did not reveal an increased risk. Probably the power in
hese subgroup analyses was limited to observe statistically signif-
cant excess mortality in case of paternal inheritance.
Second, we did not know the cause of death; however, by com-
aring a relatively rare disorder with the population at large and
djustment for the differences in the distribution of sex, calendar
eriod and age category, we could determine the excess mortal-
ty resulting from FH. Speciﬁc causes of death are less reliable
ndpoints than all cause mortality due to low accuracy of death
ertiﬁcates, even in current times and especially for cardiovascu-
ar causes of death [28,29]. The mortality rates in this pedigree
ere in line with the expected burden from untreated FH; CHD
isk is approximately seven times increased by heterozygosity for
he V408M mutation [12]. Third, in the present study, effects of
aternal hypercholesterolemia on cholesterol levels could not be
alculated, due to small numbers of known untreated cholesterol
evels. Recently, in a study consisting of patients largely identiﬁed
y our genetic cascade screening, it was shown that children who
nherited FH from their mothers had higher LDL cholesterol levels
30].
Fourth, we did not study the effects of hypercholesterolemic
others on the non-FH offspring since it is impossible to assign
non-FH”with100%certainty innon-tested individuals in thispedi-
ree. This is unfortunate, because it might be hypothesized that
his offspring has a higher mortality risk as well. Finally, it could
e argued that paternal FH might have other (postnatal) conse-
uences for the offspring: ‘today, extreme premature CHD of the
ather may have led to a healthier lifestyle of the offspring’. How-
ver, the majority of persons in this pedigree lived in times during
hich cholesterolwas unknownand lifestyle interventions hadnot
een developed.
In conclusion, we demonstrate that mortality rates are more
ncreased when FH is inherited through the mother, supporting
he fetal origin of adulthood disease hypothesis with all cause
eath, the most indisputable outcome measure. Future research
hould further explore this interaction and eventually safe options
or cholesterol-lowering therapy of pregnant women with FH in
rder to prevent unfavourable epigenetic consequences leading to
therosclerosis in their children.
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